EGFR and triple-negative breast carcinoma: It has been demonstrated that the triple-negative breast cancer cell line (BT-20) is sensitive to sequential and time-dependent combinatorial drug treatments using the EGFR inhibitor Erlotinib and DNA damage inducer Doxorubicin15.